Skip to main navigation
Skip to search
Skip to main content
Penn State Home
Help & FAQ
Link opens in a new tab
Search content at Penn State
Home
Researchers
Research output
Research units
Equipment
Grants & Projects
Prizes
Activities
Leptomeningeal metastatic disease: new frontiers and future directions
Ahmad Ozair
, Hannah Wilding
, Debarati Bhanja
, Nicholas Mikolajewicz
, Michael Glantz
, Stuart A. Grossman
, Arjun Sahgal
, Emilie Le Rhun
, Michael Weller
, Tobias Weiss
, Tracy T. Batchelor
, Patrick Y. Wen
, Daphne A. Haas-Kogan
, Mustafa Khasraw
, Roberta Rudà
, Riccardo Soffietti
, Philipp Vollmuth
, Vivek Subbiah
, Chetan Bettegowda
, Lily C. Pham
Graeme F. Woodworth, Manmeet S. Ahluwalia,
Alireza Mansouri
Show 3 others
Show less
Department of Neurosurgery
Penn State Cancer Institute
Cancer Institute, Experimental Therapeutics
Penn State Neuroscience Institute
Research output
:
Contribution to journal
›
Review article
›
peer-review
33
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Leptomeningeal metastatic disease: new frontiers and future directions'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Metastatic Disease
100%
New Frontiers
100%
Leptomeningeal
100%
Cerebrospinal Fluid
60%
Cell-based
20%
Tool Development
20%
Proton
20%
Unique Mechanism
20%
Plexus
20%
Scarce Resources
20%
Novel Therapeutics
20%
Tumor-associated Macrophages
20%
Brain Metastases
20%
Disease-specific
20%
Flow Studies
20%
Targeted Therapy
20%
Neuro-oncology
20%
Cancer Cell Survival
20%
Cell Attachment
20%
Pharmacokinetic Evaluation
20%
Adaptive Design
20%
Disease Surveillance
20%
Response Assessment
20%
Intrathecal
20%
Antibody-drug Conjugate
20%
Cerebrospinal Fluid Flow
20%
Phase Trials
20%
Prospective Registry
20%
Complement System
20%
Liquid Biopsy
20%
Branched-chain Keto Acids
20%
Intrathecal Drug Delivery
20%
Core Outcome Set
20%
Diagnostic Confirmation
20%
Leptomeninges
20%
Multi-omics Analysis
20%
Targeted Immunotherapy
20%
Elevated Levels
20%
Trial Testing
20%
Biochemistry, Genetics and Molecular Biology
Cancer Cell
100%
Cell Survival
50%
Tumor-Associated Macrophage
50%
Dendritic Cell
50%
Pharmacodynamics
50%
Pharmacokinetics
50%
Conjugate
50%
Complement System
50%
Adaptive Clinical Trial
50%
Cerebrospinal Fluid Flow
50%
Targeted Therapy
50%
Liquid Biopsy
50%
Multi-Omics
50%
Neuroscience
Intrathecal
100%
Cell Survival
50%
Macrophage
50%
Immunotherapy
50%
Cerebrospinal Fluid Flow
50%
Pharmacokinetics
50%
Complement System
50%
Leptomeninx
50%
Keto Acids
50%
Pia Mater
50%
Multi-Omics
50%
Immunology and Microbiology
Cerebrospinal Fluid
100%
Cancer Cell
66%
Cell Survival
33%
Pharmacokinetics
33%
Immunotherapy
33%
Conjugate
33%
Multi-Omics
33%
Cerebrospinal Fluid Flow
33%
Tumor-Associated Macrophage
33%
Dendritic Cell Vaccine
33%
Complement System
33%
Pharmacodynamics
33%
Leptomeninx
33%